<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3384">
  <stage>Registered</stage>
  <submitdate>1/12/2011</submitdate>
  <approvaldate>1/12/2011</approvaldate>
  <nctid>NCT01484275</nctid>
  <trial_identification>
    <studytitle>A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma</studytitle>
    <scientifictitle>A Phase 2, Randomized, Blinded, Placebo-controlled, Multicenter Study of Siltuximab (Anti IL 6 Monoclonal Antibody) in Subjects With High-risk Smoldering Multiple Myeloma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CNTO328SMM2001</secondaryid>
    <secondaryid>CR100755</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>High-risk Smoldering Multiple Myeloma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Siltuximab
Treatment: drugs - Placebo

Experimental: Siltuximab - Type=exact, unit=mg/kg, number=15, form=intravenous infusion, route=intravenous use, every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.

Placebo Comparator: Placebo - Form=intravenous infusion, route=intravenous use route=intravenous, use every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.


Treatment: drugs: Siltuximab
Type=exact, unit=mg/kg, number=15, form=intravenous infusion, route=intravenous use, every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.

Treatment: drugs: Placebo
Form=intravenous infusion, route=intravenous use route=intravenous, use every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>One-year progression-free survival (PFS) rate - Defined by CRAB - IMWG (calcium, renal, anemia, and bone lesions - International Myeloma Working Group) criteria.</outcome>
      <timepoint>6 months after 74th participant is randomized</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free survival (PFS) - Based on CRAB criteria.</outcome>
      <timepoint>Up to approximately 4 years after randomization of last patient</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progressive Disease (PD) indicator rate - Novel composite endpoint, built from potential early signs of progression to multiple myeloma.</outcome>
      <timepoint>6 months after 74th participant is randomized</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire-Core 30 (EORTC QLQ C30) - The questionnaire includes 9 scales: 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, nausea and vomiting, and pain), 6 single-item scales (dyspnea, insomnia, anorexia, constipation, diarrhea and financial impact) and single-item global health and quality of life scales.</outcome>
      <timepoint>Up to approximately 4 years after randomization of last patient</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Brief Pain Inventory (worst pain item) - Refers to the "worst" pain the patient has experienced over the past 24 hours.</outcome>
      <timepoint>Up to approximately 4 years after randomization of last patient</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in clinical laboratory values</outcome>
      <timepoint>Up to approximately 4 years after randomization of last patient</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of participants experiencing adverse events</outcome>
      <timepoint>Up to approximately 4 years after randomization of last patient</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>Approximately 4 years after randomization of last patient</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Diagnosis of smoldering multiple myeloma (SMM) for &lt;4 years

          -  Diagnosis of high-risk SMM (defined as bone marrow plasma cells &gt;=10% and either serum
             monoclonal protein &gt;=3 g/dL, or abnormal free light chain ratio &lt;0.126 or &gt;8 and serum
             M-protein &lt;3 g/dL but &gt;=1 g/dL)

          -  Patients must be within certain limits for protocol-specified laboratory tests

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1

          -  Women not of childbearing potential must be postmenopausal, permanently sterilized, or
             otherwise incapable of pregnancy

          -  Women of childbearing potential must agree to use adequate birth control measures and
             agree to not donate eggs for the purpose of assisted reproduction during the study and
             for 3 months after receiving the last dose of study agent, and must have a negative
             pregnancy test at screening

          -  Men must agree to use a double-barrier method of birth control and to not donate sperm
             during the study and for 3 months after receiving the last dose of study agent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Having symptomatic multiple myeloma, defined by any of the following (if due to
             myeloma): lytic bone lesions, severe osteopenia (low bone density), pathologic
             fractures, hypercalcemia (too much calcium in the blood), kidney insufficiency;
             symptomatic hyperviscosity of the blood, or recurrent serious bacterial infections
             such as pneumonia

          -  Primary systemic amyloid light (AL) chain amyloidosis (a build-up of amyloid light
             chain proteins in the blood)

          -  Prior or concurrent exposure to approved or investigational multiple myeloma
             treatments (concurrent treatment with bone-protecting agents (eg, bisphosphonates,
             denosumab), or steroids (not exceeding 10 mg prednisone per day or equivalent) are
             only allowed if given in a stable dose and for a nonmalignant condition; concurrent
             treatment with erythropoietin-stimulating agents (ESAs) are not allowed.)

          -  Prior exposure to agents targeting interleukin 6 (IL 6) or the IL 6 receptor

          -  Other malignancy within the past 3 years, except for the following, if treated and not
             active: basal cell or nonmetastatic (non-spreading) squamous cell carcinoma of the
             skin, cervical carcinoma or International Federation of Gynecology and Obstetrics
             Stage 1 carcinoma of the cervix</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>87</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/08/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Camperdown</hospital>
    <hospital> - East Melbourne</hospital>
    <hospital> - Randwick</hospital>
    <postcode> - Camperdown</postcode>
    <postcode> - East Melbourne</postcode>
    <postcode> - Randwick</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerpen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Dijon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes Cedex 1</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Tours</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ashkelon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Nahariya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Netanya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petach Tikva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daejeon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcleona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Salamanca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>GÃ¶teborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Linkoping</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Janssen Research &amp; Development, LLC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the safety and efficacy of siltuximab compared with
      placebo (an inactive substance that is compared with a drug to test whether the drug has a
      real effect in a clinical trial) in patients with high-risk smoldering multiple myeloma
      (SMM).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01484275</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Janssen Research &amp; Development, LLC Clinical Trial</name>
      <address>Janssen Research &amp; Development, LLC</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>